Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
Anticipating and managing CDK4/6 inhibitor toxicities in HR+ HER2- breast cancer is essential to improving patient quality of life and optimizing clinical outcomes. In this episode, CANCER BUZZ speaks with Diana Van Ostran, PharmD, BCOP, clinical pharmacy specialist – breast clinic at Miami Cancer Institute, Baptist Health South Florida, about strategies to monitor and manage treatment-related adverse events in patients with early-stage and metastatic breast cancer receiving CDK4/6 inhibitors. She discusses the importance of individualized care and robust patient education around lifestyle and dietary techniques to improve tolerance of this treatment.
Guests:
Diana Van Ostran, PharmD, BCOP
Clinical Pharmacy Specialist – Breast Clinic
Miami Cancer Institute
Baptist Health South Florida
Miami, FL
“Clinical pharmacists play a vital role in managing the patient's treatment. Because, as we know, if you're having excessive side effects, patients are going to be less likely to take their medications.”
Resources:
ACCC Adverse Event Management for CDK Inhibitors in HR+ Breast Cancer
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
June 30, 2026
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
